Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Can next-generation antibodies offset biosimilar competition?

Nature Reviews Drug Discovery volume 11, pages 426–428 (2012)Cite this article

Subjects

With the first biosimilar version of a monoclonal antibody now under regulatory review in the European Union, which R&D strategies are innovators relying on to counteract competition?

Since the technology to produce monoclonal antibodies (mAbs) came of age in the 1990s, drug developers have embraced mAbs as a therapeutic modality and commercial saviour. The properties of these biologics provided new ways to pursue 'undruggable' targets, and their complexity promised an additional buffer against generic competition and the small-molecule patent cliff that was becoming apparent. Investment in the development of mAbs swelled, and next year six out of ten of the top-selling drugs are expected to be antibody-based therapeutics.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Authors
  1. Asher Mullard
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mullard, A. Can next-generation antibodies offset biosimilar competition?. Nat Rev Drug Discov 11, 426–428 (2012). https://doi.org/10.1038/nrd3749

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3749

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing